The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.
ModBase Predicted Comparative 3D Structure on Q16543
Front
Top
Side
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.
Orthologous Genes in Other Species
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
Biological Process: GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0006457 protein folding GO:0006605 protein targeting GO:0010608 posttranscriptional regulation of gene expression GO:0018108 peptidyl-tyrosine phosphorylation GO:0038128 ERBB2 signaling pathway GO:0045859 regulation of protein kinase activity GO:0050821 protein stabilization GO:0060334 regulation of interferon-gamma-mediated signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0098779 mitophagy in response to mitochondrial depolarization
U43077 - Human CDC37 homolog mRNA, complete cds. BC000083 - Homo sapiens cell division cycle 37 homolog (S. cerevisiae), mRNA (cDNA clone MGC:3241 IMAGE:3505011), complete cds. BC008793 - Homo sapiens cell division cycle 37 homolog (S. cerevisiae), mRNA (cDNA clone MGC:3863 IMAGE:3619769), complete cds. JD565506 - Sequence 546530 from Patent EP1572962. JD208127 - Sequence 189151 from Patent EP1572962. JD526375 - Sequence 507399 from Patent EP1572962. JD500608 - Sequence 481632 from Patent EP1572962. JD368049 - Sequence 349073 from Patent EP1572962. JD418698 - Sequence 399722 from Patent EP1572962. JD226386 - Sequence 207410 from Patent EP1572962. JD474426 - Sequence 455450 from Patent EP1572962. JD520681 - Sequence 501705 from Patent EP1572962. JD202200 - Sequence 183224 from Patent EP1572962. JD477121 - Sequence 458145 from Patent EP1572962. JD477120 - Sequence 458144 from Patent EP1572962. JD175000 - Sequence 156024 from Patent EP1572962. U63131 - Human CDC37 homolog mRNA, complete cds. JD056191 - Sequence 37215 from Patent EP1572962. BC127212 - Homo sapiens methyl-CpG binding domain protein 5, mRNA (cDNA clone IMAGE:40082535), partial cds. BC127213 - Homo sapiens methyl-CpG binding domain protein 5, mRNA (cDNA clone IMAGE:40082536), partial cds. BC141928 - Homo sapiens cell division cycle 37 homolog (S. cerevisiae), mRNA (cDNA clone IMAGE:40082537), partial cds. BC141929 - Homo sapiens cell division cycle 37 homolog (S. cerevisiae), mRNA (cDNA clone IMAGE:40082538), partial cds. CR542249 - Homo sapiens full open reading frame cDNA clone RZPDo834A0526D for gene CDC37, CDC37 cell division cycle 37 homolog (S. cerevisiae); complete cds, incl. stopcodon. BT006796 - Homo sapiens CDC37 cell division cycle 37 homolog (S. cerevisiae) mRNA, complete cds. DQ892174 - Synthetic construct clone IMAGE:100004804; FLH183691.01X; RZPDo839F06142D CDC37 cell division cycle 37 homolog (S. cerevisiae) (CDC37) gene, encodes complete protein. DQ895369 - Synthetic construct Homo sapiens clone IMAGE:100009829; FLH183687.01L; RZPDo839F06141D CDC37 cell division cycle 37 homolog (S. cerevisiae) (CDC37) gene, encodes complete protein. AB463478 - Synthetic construct DNA, clone: pF1KB8347, Homo sapiens CDC37 gene for cell division cycle 37 homolog, without stop codon, in Flexi system. AM393285 - Synthetic construct Homo sapiens clone IMAGE:100002242 for hypothetical protein (CDC37 gene). AM393349 - Synthetic construct Homo sapiens clone IMAGE:100002243 for hypothetical protein (CDC37 gene). LZ238858 - WO 2017171048-A/519: Kit, device and method for detecting early pancreatic cancer or precancerous lesion of pancreas. HZ408805 - JP 2015528002-A/1402: CHIRAL CONTROL. LG052139 - KR 1020150036642-A/1405: CHIRAL CONTROL. LP837144 - Sequence 18 from Patent WO2017108491. LP942656 - Sequence 18 from Patent EP3184645. LZ238591 - WO 2017171048-A/252: Kit, device and method for detecting early pancreatic cancer or precancerous lesion of pancreas. JD408654 - Sequence 389678 from Patent EP1572962. HI965579 - Sequence 864 from Patent WO2010139812. HI966474 - Sequence 794 from Patent WO2010139811. HI967340 - Sequence 794 from Patent WO2010139810. HV594753 - JP 2010539959-A/134: Micromirs. HW122383 - JP 2013504331-A/42: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY. HW413562 - WO 2014003053-A/11: Method for screening pancreatic cancer and test kit therefor. HW799010 - WO 2014192907-A/116: Method for detecting miRNA used for differentiating disorders causing motor neuropathy. HZ074642 - JP 2013535982-A/733: Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer. HZ083368 - JP 2015513906-A/725: Stem Cell Microparticles. HZ157310 - JP 2015130862-A/134: Micromirs. HZ437149 - JP 2015529450-A/725: Stem Cell Microparticles. HZ479632 - JP 2015535430-A/138: TERMINALLY MODIFIED RNA. HZ789563 - JP 2016504050-A/1308: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. JA401617 - Sequence 864 from Patent WO2011080318. JA402595 - Sequence 864 from Patent WO2011080315. JA403602 - Sequence 864 from Patent WO2011080316. JA406233 - Sequence 864 from Patent EP2336353. JA426716 - Sequence 49 from Patent WO2011072177. JA429759 - Sequence 864 from Patent WO2011095623. JA791876 - Sequence 278 from Patent WO2012089772. JB022504 - Sequence 346 from Patent WO2013026685. JB050140 - Sequence 227 from Patent WO2013020926. JB249318 - Sequence 86 from Patent EP2478360. JB620827 - Sequence 807 from Patent WO2013063544. JC172353 - Sequence 725 from Patent WO2013150303. JC512295 - Sequence 2548 from Patent WO2014113089. JC573164 - Sequence 725 from Patent WO2014125276. JC582852 - Sequence 725 from Patent WO2014125277. JE954548 - Sequence 725 from Patent WO2015052526. JE956301 - Sequence 725 from Patent WO2015052527. LF138053 - JP 2016507550-A/725: Method of Producing Microparticles. LF161599 - JP 2016513950-A/1665: Oligomers with improved off-target profile. LF163018 - JP 2016513095-A/725: Stem Cell Microparticles and miRNA. LF636382 - JP 2016519076-A/156: COMBINATION CANCER TREATMENTS UTILIZING MICRORNA AND EGFR-TKI INHIBITORS. LF953770 - JP 2016534103-A/725: Stem Cell Microparticles and miRNA. LG006115 - KR 1020150004822-A/725: STEM CELL MICROPARTICLES. LG053811 - KR 1020150059168-A/725: STEM CELL MICROPARTICLES. LG134539 - KR 1020150131312-A/157: COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS. LG241050 - KR 1020160035087-A/725: STEM CELL MICROPARTICLES AND MIRNA. LP727100 - Sequence 794 from Patent EP2883966. LP819370 - Sequence 794 from Patent EP3296406. LP837130 - Sequence 4 from Patent WO2017108491. LP939312 - Sequence 794 from Patent EP3184651. LP942642 - Sequence 4 from Patent EP3184645. LQ069883 - Sequence 207 from Patent EP2964234. LQ278553 - Sequence 92 from Patent WO2016066288. LV471135 - JP 2016534036-A/725: Stem Cell Microparticles and miRNA. LX280755 - JP 2016105097-A/42: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY. LY404818 - KR 1020160117535-A/123: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. LZ234373 - JP 2017181518-A/42: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY. LZ238341 - WO 2017171048-A/2: Kit, device and method for detecting early pancreatic cancer or precancerous lesion of pancreas. MA260057 - JP 2017505623-A/123: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES. MS834718 - Sequence 864 from Patent EP3112479. MS901873 - Sequence 346 from Patent EP3156505. MA643384 - JP 2017113010-A/1308: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA731268 - JP 2017140048-A/138: TERMINALLY MODIFIED RNA. MA405413 - WO 2018155427-A/187: A probe with reduced false positive binding, a method to desing the probe, and the use thereof. MA806498 - WO 2018199275-A/758: Kit, device and method for detection of ovary tumor. MA806225 - WO 2018199275-A/485: Kit, device and method for detection of ovary tumor. MA800437 - JP 2018183181-A/1308: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES. MA805953 - WO 2018199275-A/213: Kit, device and method for detection of ovary tumor. MA822856 - WO 2019004436-A/669: Kit, device, and method for detection of lung cancer. MA822524 - WO 2019004436-A/337: Kit, device, and method for detection of lung cancer. MA822195 - WO 2019004436-A/8: Kit, device, and method for detection of lung cancer. MP129825 - Sequence 725 from Patent EP3470073. MP162748 - Sequence 725 from Patent WO2019069093. LY616622 - KR 1020180129785-A/519: KIT OR DEVICE FOR DETECTING EARLY STAGE PANCREATIC CANCER OR PANCREATIC CANCER PRECURSOR LESIONS AND DETECTION METHOD THEREFOR. LY616355 - KR 1020180129785-A/252: KIT OR DEVICE FOR DETECTING EARLY STAGE PANCREATIC CANCER OR PANCREATIC CANCER PRECURSOR LESIONS AND DETECTION METHOD THEREFOR. LY616105 - KR 1020180129785-A/2: KIT OR DEVICE FOR DETECTING EARLY STAGE PANCREATIC CANCER OR PANCREATIC CANCER PRECURSOR LESIONS AND DETECTION METHOD THEREFOR.
Biochemical and Signaling Pathways
Reactome (by CSHL, EBI, and GO)
Protein Q16543 (Reactome details) participates in the following event(s):
R-HSA-1218833 Binding of ligand-responsive EGFR mutants to chaperoning proteins HSP90 and CDC37 R-HSA-1247999 EGFRvIII mutant binds chaperone proteins HSP90 and CDC37. R-HSA-1963589 ERBB2 forms heterodimers with ligand-activated ERBB receptors: EGFR, ERBB3 and ERBB4 R-HSA-1918092 CHIP (STUB1) mediates ubiquitination of ERBB2 R-HSA-1918095 CUL5 mediates ubiquitination of ERBB2 R-HSA-1248002 Ligand-independent dimerization of EGFRvIII mutant R-HSA-1220613 EGF-induced dimerization of ligand-responsive EGFR mutants R-HSA-1220612 Binding of EGF to ligand-responsive EGFR mutants R-HSA-1220614 Spontaneous dimerization of ligand-responsive EGFR mutants R-HSA-1248655 Trans-autophosphorylation of EGFRvIII mutant dimers R-HSA-5637764 Binding of GRB2:GAB1:PIK3R1 complex to p-EGFRvIII mutant R-HSA-5637766 Binding of SHC1 to p-5Y-EGFRvIII R-HSA-5637770 Binding of GRB2:SOS1 complex to phosphorylated EGFRvIII R-HSA-5637792 PLC-gamma 1 binds to p-EGFRvIII mutant R-HSA-5637800 Dissociation of phosphorylated PLC-gamma 1 from p-EGFRvIII mutant R-HSA-1220611 Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors R-HSA-1220610 Non-covalent tyrosine kinase inhibitors bind and inactivate sensitive ligand-responsive EGFR cancer mutants R-HSA-5637765 Binding of PI3K p110 subunit alpha (PIK3CA) to complex of GRB2:GAB1:PIK3R1 and p-EGFRvIII R-HSA-5637795 Phosphorylation of PLC-gamma 1 by p-EGFRvIII mutant R-HSA-5637796 Phosphorylation of SHC1 by p-5Y-EGFRvIII R-HSA-5637798 Phosphorylated SHC1 in complex with p-5Y-EGFRvIII recruits GRB2:SOS1 complex R-HSA-1169421 Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers R-HSA-5637806 SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with p-EGFRvIII) R-HSA-1225947 Binding of SHC1 to p-6Y-EGFR mutants R-HSA-1225949 Binding of CBL to ligand-responsive p-6Y-EGFR mutants R-HSA-1225950 Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants R-HSA-1226016 Binding of GRB2:GAB1:PIK3R1 complex to ligand-responsive p-6Y-EGFR mutants R-HSA-1247841 PLCG1 binds to ligand-responsive p-6Y-EGFR mutants R-HSA-1247842 Dissociation of phosphorylated PLCG1 from ligand-responsive p-6Y-EGFR mutants R-HSA-5637801 Conversion of PIP2 to PIP3 by PI3K bound to phosphorylated EGFRvIII R-HSA-5637808 SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and p-EGFRvIII) R-HSA-1225961 Phosphorylated SHC1 in complex with ligand-responsive p-6Y-EGFR mutants recruits GRB2:SOS1 complex R-HSA-1225952 Phosphorylation of SHC1 by ligand-responsive p-6Y-EGFR mutants R-HSA-1225960 Phosphorylation of CBL by ligand-responsive p-6Y-EGFR mutants R-HSA-1226012 Binding of PI3K p110 subunit alpha (PIK3CA) to complex of GRB2:GAB1:PIK3R1 and ligand-responsive p-6Y-EGFR mutants R-HSA-1247844 Phosphorylation of PLCG1 by ligand-responsive p-6Y-EGFR mutants R-HSA-1225951 SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants) R-HSA-1225957 SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants) R-HSA-1226014 Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants R-HSA-1236382 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants R-HSA-5637810 Constitutive Signaling by EGFRvIII R-HSA-1227986 Signaling by ERBB2 R-HSA-8863795 Downregulation of ERBB2 signaling R-HSA-5637815 Signaling by Ligand-Responsive EGFR Variants in Cancer R-HSA-5637812 Signaling by EGFRvIII in Cancer R-HSA-9006934 Signaling by Receptor Tyrosine Kinases R-HSA-1643713 Signaling by EGFR in Cancer R-HSA-162582 Signal Transduction R-HSA-5663202 Diseases of signal transduction R-HSA-1643685 Disease
US Server
Sequence and Links to Tools and Databases 
Common Gene Haplotype Alleles 
